CAR-T Meeting 2021 | Novel strategies to optimize CAR T-cell therapy

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses approaches to optimize CAR T-cell therapy. CAR T-cell therapies have achieved impressive outcomes in hematological malignancies. However, setbacks such as limited CAR T-cell persistence after infusion, high relapse rates, resistance, and toxicities continue to be experienced. Prof. Nagler outlines novel strategies to improve CAR T-cell function, including novel constructs, new targets, bispecific CAR-T cells, and allogeneic CAR-Ts. This interview took place during the 3rd European CAR T-cell Meeting.